Genzyme Sues Watson Over Renvela Powder ANDA

Law360, New York (July 12, 2010, 3:09 PM EDT) -- Genzyme Corp. has filed a patent infringement suit in an effort to block a Watson Pharmaceuticals Inc. unit from producing a generic version of kidney disease treatment Renvela in powder form, on the heels of a dispute between the rivals over the tablet form of the drug.

Genzyme lodged its complaint Friday in the U.S. District Court for the District of Maryland, alleging that Watson Laboratories Inc. committed an act of infringement by submitting an abbreviated new drug application seeking approval to manufacture and sell 2.4...
To view the full article, register now.